Genetics meets epigenetics: Genetic variants that modulate noncoding RNA in cardiovascular diseases
Martina Calore1, Leon J De Windt1, Alessandra Rampazzo2
1Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, 6229 ER Maastricht, The Netherlands.
Journal of Molecular and Cellular Cardiology
|November 8, 2015
Summary
Genetic variations in noncoding RNAs (ncRNAs) and their targets influence gene expression and are linked to cardiovascular diseases. This review explores the impact of these variations on cardiovascular health.
Area of Science:
- Genomics
- Molecular Biology
- Cardiovascular Medicine
Background:
- The human genome description revealed extensive noncoding RNA (ncRNA) regions.
- ncRNAs, including microRNAs and long ncRNAs, regulate gene expression and are implicated in diseases.
- Genetic variations within ncRNAs and their targets can affect gene regulation.
Purpose of the Study:
- To review the role of genetic variations in ncRNAs and their targets in cardiovascular diseases.
- To provide an overview of how these variations contribute to adverse cardiovascular phenotypes.
Main Methods:
- Literature review of studies investigating genetic polymorphisms in ncRNAs and cardiovascular outcomes.
- Analysis of reported associations between ncRNA variants and cardiovascular diseases.
Main Results:
- Common genetic variants can alter ncRNA expression levels and functionality.
- Polymorphisms in ncRNAs or their target genes are associated with cardiovascular adverse phenotypes.
- These variations lead to differential regulation of target genes, impacting cardiovascular health.
Conclusions:
- Genetic variations in ncRNAs and their targets are significant factors in cardiovascular disease development.
- Understanding these variations is crucial for comprehending the genetic basis of cardiovascular conditions.
- Further research into ncRNA genetics may offer new insights into cardiovascular disease mechanisms and treatments.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:27Principles of Pharmacogenetics: Types of Genetic Variants
95
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
01:29Pharmacogenomics: Identification of New Drug Targets
77
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
01:32RNA Splicing
61.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.4K
02:39lncRNA - Long Non-coding RNAs
10.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
02:39lncRNA - Long Non-coding RNAs
3.8K
3.8K